Charles River Laboratories International (NYSE:CRL) Updates FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL - Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $9.10-$9.60 for the period, compared to the consensus earnings per share estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $0.86 during midday trading on Friday, reaching $163.11. 1,215,947 shares of the company were exchanged, compared to its average volume of 1,060,465. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37. The company's 50 day moving average price is $172.84 and its two-hundred day moving average price is $188.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the firm earned $2.46 EPS. Charles River Laboratories International's revenue was down 1.1% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories International will post 9.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent analyst reports. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. StockNews.com cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, UBS Group reaffirmed a "neutral" rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $195.71.

Insider Transactions at Charles River Laboratories International

In other news, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Birgit Girshick bought 1,514 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).